Charles River Laboratories International, Inc. (CRL) is scheduled to report first-quarter 2025 results on May 7, before market open. In the last reported quarter, the company's adjusted earnings per share (EPS) of $2.66 surpassed the Zacks Consensus Estimate by 6.4%. Earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 10.22%. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.) CRL's Q1 Estimates The Zacks Consensus Estimate for revenues ...

With a robust academic background including an MBA in Finance from NYU-Stern, and an MD from Delhi University, my journey in the financial world has been diverse and enriching. My postgraduate training in medicine was conducted at Harvard and Cornell affiliated hospitals, thus laying a solid foundation for my current expertise.As a registered investment advisor and professional money manager, I bring nearly a decade of experience in writing about income investing and biotech/pharma investing. My role at Vas ...

It’s been a turbulent start to 2025 for investors. The market has faced a wave of selling pressure driven by surging tariffs, escalating geopolitical tensions, and growing fears of a global economic slowdown. The S&P 500, tracked by the popular SPDR ETF NYSEARCA: SPY, is now down 8% year-to-date and more than 12% off its 52-week high. However, there has been a glimmer of relief. After former President Trump announced a 90-day tariff pause for countries that refrained from retaliating against the U.S., the m ...

Charles River Laboratories (CRL) shares rallied 6.9% in the last trading session to close at $106.60. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 41.7% loss over the past four weeks.Charles River scored a strong price increase on investors’ optimism driven by the company’s impending first-quarter 2025 results, expected to release on May 8 before the market opens. In the last reported fourth quarter, both ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Charles River Laboratories (CRL) , which belongs to the Zacks Medical Services industry, could be a great candidate to consider.This medical research equipment and services provider has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 6.49%.For the ...

Core Viewpoint - Aldeyra Therapeutics, Inc. experienced a significant decline of 74% on April 3rd following the receipt of a Complete Response Letter from the FDA regarding its New Drug Application for reproxalap, intended for the treatment of dry eye disease [1] Company Summary - Aldeyra Therapeutics, Inc. is focused on developing reproxalap for dry eye disease, but faced a setback with the FDA's Complete Response Letter [1] - The company's stock performance was severely impacted, indicating potential investor concerns regarding the future of reproxalap and its market viability [1] Industry Context - The incident highlights the challenges faced by biotech companies in obtaining FDA approval, which can significantly affect stock prices and investor sentiment [1]

Core Insights - Charles River Laboratories International, Inc. (CRL) and Valo Health, Inc. have announced an advanced product candidate for treating lupus and other autoimmune diseases, utilizing Logica, an AI-powered drug development solution [1][5] - Logica represents a strategic collaboration that integrates Valo Health's AI capabilities with Charles River's drug discovery expertise, marking a significant advancement in the industry [3] - The Logica platform consists of two products: Logica Advanceable Lead (Logica-AL) and Logica Candidate (Logica-C), designed to optimize the drug development process [4] Company Developments - Charles River has signed an agreement with Singapore General Hospital to provide compliant master cell banking and next-generation sequencing services for cancer treatment [6] - The identification of the first lead candidate through Logica serves as proof of concept for enhancing drug discovery in critical therapeutic areas [5] Industry Prospects - The global autoimmune disease diagnostics market was valued at $5.39 billion in 2023 and is expected to grow at a compound annual growth rate of 6.2% through 2030, driven by increased awareness and technological advancements [7] Peer Updates - Thermo Fisher Scientific has launched the CorEvitas Systemic Lupus Erythematosus Registry to collect real-world data on lupus, complementing its biorepository for drug discovery [9] - Abbott has received FDA Investigational Device Exemption for its Coronary Intravascular Lithotripsy system, targeting severe calcification in coronary arteries [11] - Bio-Rad has made a binding offer to acquire Stilla Technologies and led a $105 million funding round for Geneoscopy, Inc. to support colorectal cancer screening innovations [13][14]

Have you looked into how Charles River Laboratories (CRL) performed internationally during the quarter ending December 2024? Considering the widespread global presence of this medical research equipment and services provider, examining the trends in international revenues is essential for assessing its financial resilience and prospects for growth.In the current era of a tightly interconnected global economy, the proficiency of a company to penetrate international markets significantly influences its financ ...

Charles River Laboratories 4Q 2024 Results & 2025 Guidance February 19, 2025 © 2025 Charles River Laboratories International, Inc. Safe Harbor Caution Concerning Forward-Looking Statements. This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate," "believe," "expect," "intend," "will," "may," "estimate," "plan," "outlook," and "project" and other simi ...

Financial Data and Key Metrics Changes - The company reported fourth-quarter revenue of $1 billion, representing a 1.8% decline on an organic basis from the previous year [15] - For the full year, revenue was $4.05 billion, with an organic revenue decrease of 2.8%, primarily driven by lower DSA revenue [15] - The operating margin increased by 80 basis points year over year to 19.9% in the fourth quarter, while the full-year operating margin declined by 40 basis points to 19.9% [16][17] - Earnings per share for the fourth quarter were $2.66, an increase of 8.1% from $2.46 in the fourth quarter of 2023 [17] Business Line Data and Key Metrics Changes - DSA revenue in the fourth quarter was $603.3 million, a decrease of 3.5% on an organic basis, reflecting lower study volume and slightly lower pricing [19] - RMS revenue in the fourth quarter was $204.3 million, a decrease of 0.4% on an organic basis, while full-year RMS revenue was essentially flat with a 0.1% decline [29] - Manufacturing solutions revenue was $194.9 million in the fourth quarter, with a growth rate of 2.1% on an organic basis, and a full-year organic growth rate of 6.8% [36] Market Data and Key Metrics Changes - The DSA backlog declined to $1.97 billion from $2.12 billion at the end of the third quarter [22] - The net book-to-bill ratio remained below one times in the fourth quarter, consistent with the third quarter [20] - The company expects DSA revenue to decline at a mid to high single-digit rate on an organic basis in 2025 [22] Company Strategy and Development Direction - The company is implementing restructuring initiatives expected to yield annualized savings of approximately $225 million by 2026, with over $175 million realized in 2025 [14][50] - The focus is on enhancing client experience and gaining market share through commercial enhancements and strategic pricing [43][44] - The company plans to allocate approximately $350 million to stock repurchases in 2025 under a $1 billion authorization [45][51] Management's Comments on Operating Environment and Future Outlook - The management views the biopharmaceutical demand environment as stabilizing, with expectations for a revenue decline of 4.5% to 7% in 2025, including foreign exchange headwinds [13][53] - There is cautious optimism regarding biotech demand, which is expected to be stable to slightly improved in 2025 [11][41] - The management does not anticipate a recovery in 2025 but is taking decisive actions to manage costs and protect shareholder value [42][64] Other Important Information - The company is closely monitoring the supply chain for non-human primates (NHPs) and has diversified sourcing arrangements to mitigate risks [25][96] - The non-GAAP tax rate for 2025 is expected to be in the range of 22.5% to 23.5%, an increase from 21.3% in 2024 [57] Q&A Session Summary Question: About bookings and backlog - The fourth quarter's net book-to-bill was stable, with no deterioration or improvement [71] - The first quarter is expected to see some seasonality in DSA and Biologics, but biopharmaceutical client demand has stabilized [73] Question: Academic and government exposure - Academic and government clients represent about 40% of RMS, with direct NIH exposure at less than 2% [78] Question: Large pharma demand and recovery expectations - The management does not anticipate further deterioration in pharma demand but expects stability throughout the year [84] Question: CDMO business and margin impact - Margins in the CDMO business will be challenged, but actions are being taken to right-size infrastructure and staffing [92] Question: CITES decision on NHP trade - The company will continue to diversify sourcing for NHPs to mitigate potential supply disruptions [96] Question: Visibility on client restructuring - The management maintains close communication with clients and does not anticipate further deterioration in demand [105]